Median lead time 2.7 months between first positive ctDNA and clinical recurrence

Transmasculine individuals have the highest acne risk in the first year after initiation of testosterone

Significant associations seen for autoimmune, endocrine, neurological, and mental health comorbidities

Significantly reduced risk for disease progression or death seen with toripalimab versus dacarbazine, including in acral melanoma

Higher percentage reductions in Eczema Area and Severity Index seen with 80 mg ICP-332, 120 mg ICP-332 versus placebo

69.5 percent of patients demonstrated improvement or remission of psoriasis after metabolic bariatric surgery for obesity

In 2024, 31.7 percent of adults and 29.5 percent of children had diagnosed seasonal allergy, eczema, or food allergy

Findings show significant risk for asthma, allergic rhinitis, or atopic dermatitis

Severity of Alopecia Tool score ≤20 at week 24 achieved by 34.9, 40.6, and 9.0 percent of patients receiving 4 mg, 8 mg ivarmacitinib,...

Median progression-free survival 7.5 months among 22 patients who underwent surgery for vaginal or vulvar melanoma

Biologics do not affect cancer progression, while predictors of progression include advanced cancer stage, higher comorbidity burden

Women had improved survival without immunotherapy, but similar survival with immunotherapy

Review of randomized controlled trials shows interventions improve psoriasis severity and quality of life

Data from four randomized clinical trials confirm benefits by day 2 in atopic dermatitis, prurigo nodularis

Negligible additional risk for recurrence seen after 5FU or surgical excision; negligible risk for cutaneous squamous cell carcinoma reported from treated BD

Furthermore, iron deficiency is associated with higher clinical burden

Significant reduction seen in the mean Worst Itch Numeric Rating Scale scores for high-, mid-, low-dose vixarelimab versus placebo

The U.S. Food and Drug Administration is reviewing bemotrizinol, a sunscreen ingredient used widely overseas

Tanning bed users more likely to have melanoma on body sites with low cumulative levels of sun damage, to have multiple melanomas

Adjusted hazard ratio for progression-free and overall survival significantly lower for NIVO3+IPI1 versus NIVO1+IPI3

Mendelian randomization analyses support effect of BMI and IBD, with no signs of pleiotropy